CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors, have demonstrated remarkable clinical benefits in the treatment of metastatic and locally advanced non-small cell lung cancer (NSCLC) [1,2,3,4].